

Phone: 770-648-8951 | www.dlsrav.com

Last Name

ACCESSION ID

Middle Initial

D.O.B.

DNexusATM **Cardio-Pulmonary** Requisition Form

Jennifer Knaack, Director CLIA ID: 11D2114053 1700 Honey Creek Commons, Suite A, Conyers GA 30013

Female

Biological Sex Male

PATIENT INFORMATION

First Name

Phone		Add	ress, City, State, Zip						
Ethnicity	African American	Asian	Native American	Hispanic	Ashkenazi Je	w White	Othe	er	
RIII	ING INFO	RMATIO	N						
								_	
Bill To	Client	Patient	Insurance (At	tach patient demog		nt and back of the	e insurance car	d)	
Insurance	Company			Name of In	sured				
Subscriber	ID		Group ID			Policy No.			
ORD	ERING PR	OVIDER	INFORMA	TION					
Ordering F	Provider				NP	1			
Address									
Provider P	hone	Fa	ıx	Email					
for the pa	to obtain the sam tient, and that the Signature						knowledge		
SPE	CIMEN INF	ORMAT	ION						
Sample T	ype Buccal Swa Other	b (Cheek Swab)	Collection Date	e	Collection Ti	ime	AM PM	Collector's	Initials
TES	T REQUEST	ΓED							
ABCC9, ACT BRAF, CACN COL9A1, CO FLNA, FLNC, (HERG), KCN MYH11, MYH PTPN11, PYC SNTA1, SOS1	Genomics Genes A2, ACTC1, ACTN2, ACVI A1C, CACNA2D1, CACNB L9A2, COL9A3, CRYAB, C GAA, F9, GATA4, GATA5 J2, KCNJ5, KCNJ8, KCNJ R1, RAF1, RANGRF, RASA' TAZ^, TBX2O^, TCAP, TE nary Genes	32, CALM1^, CALM. CSRP3, CTNNA3, D 5^, GATA6, GATAD K3, KCNQ1, KRAS, I IYL4, MYLK, MYLK 1, RBM20, RIN2, RI	2, CALM3, CASQ2, CAV1 ES, DMD, DOLK, DSC2, I 1, GDF2, GJA5, GLA, GN LAMA4, LAMP2, LDB3, L 2, MYOZ2, MYPN, NEBL, T1, RYR2, SCN10A, SCN	I, CAV3, CBS, CHRM DSE, DSG2, DSP, DTN B5, GPD1L, HCN4, HI DLR, LDLRAP1, LMNA NEXN, NKX2-5, NO IB^, SCN2B, SCN3B,	2, CHST14, COL11A IA, EFEMP2, EIF2A FE, HRAS*, ILK, JPH A, LOX, LRRC10, LT FCH1, NRAS, PCSK SCN4B, SCN5A, SG	x1, COL11A2, COL12 K4, ELN, EMD, ENG H2, JUP, KCNA5, K0 BP4, MAP2K1, MAI 9, PDLIM3, PKP2, F GCD, SHOC2, SKI,	2A1, COL1A1, CO E, EYA4, FBLN5, CND3, KCNE1, K P2K2, MAT2A, M PLN, PLOD1, PPA SLC2A10, SLC3S	PL1A2, COL2A1, CO FBN1, FBN2, FHL CONE1L, (KONE5), MED12, MFAP5, MI A2, PRDM16, PRDN PA13, SMAD2, SM	DL3A1, COL5A1, COL5A2, 1, FKBP14, FKRP*, FKTN, KCNE2, KCNE3, KCNH2, B1, MURC, MYBPC3, M5, PRKAG2, PRKG1, AD3, SMAD4, SMAD9,
CCDC39, CC ELN, FBLN5,	DC40, CFTR, CHAT, CHF FLCN, FOXF1, GAS8, GLR PPINA1, SFTPA1, SFTPA2,	A1, HPS1, HPS4, IT	GA3, LTBP4, MECP2, NA	AF1, NF1, NKX2-1, NM	IE8, PARN, PHOX2	B, PIH1D3#, RAPSN			

DIAGNOSIS

R60.9 Edema, unspecified R60.1 Generalized edema		9 Other abnormalities o	of breathing		procedural examinatio
ICD 10 CODES					

R09.89 Other speci⊡ed symptoms and signs involving the circulatory and respiratory systems

R07.9 Chest pain, unspecifie \Box d

R07.89 Other chest pain

R07.82 Intercostal pain R07.2 Precordial pain

R06.09 Other forms of dyspnea

R06.02 Shortness of breath

R06.00 Dyspnea, unspecified R05 Cough

R00.2 Palpitations

PR06.3 Periodic breathing

149.8 Other specified cardiac arrhythmias

142.5 Other restrictive cardiomyopathy

135.8 Other nonreheumatic mitral valve disorders

134.9 Nonrheumatic mitral valve disorder, unspecified

125.9 Chronic ischemic heart disease, unspecified

125.89 Other forms of chronic ischemic heart disease

125.10 Atherosclerotic heart disease of native coronary

110 Essential (Primary) Hypertension

G89.29 Other Chronic Pain

E87.1 Hypo- osmolality and / or

E78.5 Hyperlipidemia, unspecified E78.4 Other Hyperlipidemia

50.9 Heart Failure, unspecified

PATIENT SIGNATURE (REQUIRED)

By signing below, I acknowledge that the genetic test is not for diagnosing present or future diseases but aims to reveal my genetic disposition concerning health, as discussed with my healthcare provider. I have had the chance to discuss the benefits and limitations of the test with my provider, including the reliability of results. I agree not to make medical decisions based on results without consulting my healthcare provider first. I confirm that I haven't received any inducements for providing my genetic sample. I retain ownership of my medical history, and my provider cannot disclose my results without my written authorization, except for treatment or payment purposes. I understand the voluntary nature of genetic testing and have read and comprehend the document, consenting to the test and agreeing to discuss results and medical management with my healthcare provider.

	_	
Patient Signature	Date	
ratient signature	 2 4.10	



Phone: 770-648-8951 | www.dlsrav.com

Jennifer Knaack, Director CLIA ID: 11D2114053 1700 Honey Creek Commons, Suite A, Conyers GA 30013

CLINICAL HISTORY

Dislipidemias
Xanthomatosis
Other:

CEINICAL IIISTORI			
Personal history of Cardio-Pulmonary of			
Sudden Lung Failure No Yes	(if yes): # of Episodes Age of 1s	t Incident	
History of Cardiopulmonary No	Yes Age of Dx Type(s) of Ca	ardiopulmonary	
History of Arrhythmia No Yes	Age of Dx Type(s) of Arrhythm	iia	
Family or personal history of chronic bronchitis	s? Yes No Collection of uio	d in legs or belly area?	
Pulmonary edema?	Yes No Diagnosed with		
Family history of heart failure?	Diagnosed with	how the segregation of pulmonary emphysema? Yes No	
Family or personal history of a COPD?		alpha 1-antitrypsin deciency-related pulmonary	
Cardiac arrhythmias?		early onset pulmonary emphysema?	
History of right-sided heart failure?		cor pulmonale? Yes No	
CLINICAL INFORMATI	ON		
Is this person affected? Yes No	Clinical Diagnosis		
Reason for testing: Diagnosis	Pre-symptomatic diagnosis Carrier/Fo	amilial Variant Testing	
Please check all that apply:		· ·	
Diagnosis	Marfan/TAAD/HDCT	Abnormal Heart Morphology	
Amyloidosis	Aortic/Arterial aneurysm	Bicuspid aortic valve	
ARVC	Aortic/Arterial dissection	Coarctation of aorta	
Brugada syndrome	Aortic root dilation	Heart murmur	
CPVT	Arachnodactyly	Heterotaxy	
DCM	Arterial tortuosity/ectasia	Hypoplastic left heart	
Ehlers-Danlos syndrome	Arthralgia	Mitral valve prolapse	
HCM	Atypical scarring of skin	Patent ductus arteriosus	
HHT Hypertension	HHT Beighton score		
Loeys-Dietz syndrome	Bifid uvula	Tetralogy of Fallot	
LQT syndrome	Blue sclerae	Ventricular septal defect	
Noncompaction Cardiopulmonary (LVNC)	Bruising susceptibility	Atrial septal defect	
Marfan syndromeT	Cleft lip Cleft palate	Other:	
PAH	PAH		
RCM	Craniosynostosis	Pulmonary hypertension	
SQT syndrome Sudden Cardiac Arrest	Cutis laxa Dental crowding	Cardiopulmonary	
Sudden Death	Dural ectasia	Chronic bronchitis	
Echocardiogram	Ectopia lentis	Chronic obstructive pulmonary disease (COPD)	
Aortic root dimensions:	Flexion contracture	Congestive heart failure	
Z-score:	High palate	Emphysema	
EF%:	Hollow organ rupture:	Other	
LVEDD:	Uterine rupture Intestinal perfora		
Z-score: Max LV wall thickness:	Other:	Angiokeratomas Anhydrosis	
Normal	Hypertelorism	Café-Au-Lait Macules	
Report Included	Joint contractures	Hearing impairment:	
ECG	Joint dislocations	Sensorineural Conductive	
Prolonged QTc interval: Max QTc:	Joint hypermobility	Craniosynostosis	
Normal	Meets Ghent criteria	Cystic hygroma	
Report Included	Micrognathia / Retrognathia (circle what applies)	Downslanted palpebral fissures Dysmorphic features:	
Arrhythmia/Cardiopulmonary	Midface retrusion	Describe:	
Abnormal atrioventricular conduction	Mitral valve prolapse	Elevated CPK	
Atrial fibrillation	Myopia Osteoarthritis	Hypotonia	
Bradycardia	Pectus carinatum	Increase nuchal translucency	
Fatty replacement of ventricular myocardial tissue	Pectus excavatum	Intellectual disability	
Heart transplant Syncope	Pes Planus	Keratoconus	
Torsades de pointe	Pneumothorax	Muscle weakness Myopathy	
Ventricular tachycardia	Recurrent fractures	Renal insufficiency	
ннт	Retinal detachment	Short neck	
Arteriovenous malformation	Scoliosis/Kyphosis (circle what applies)	Thromboembolism	
Epistaxis	Skin findings, Specify:	Type:	
Telangiectasia Stroke			
Dislipidemias	Tall stature		
Dislipidemias Corneal Arcus LDL-C levels	Velvety skin		



Jennifer Knaack, Director CLIA ID: 11D2114053 1700 Honey Creek Commons, Suite A, Conyers GA 30013

PATIENT INFORMED CONSENT, AUTHORIZATION, AND ASSIGNMENT

I consent to have my testing performed by Prodi Lab I supplied accurate and true information with this form. If I supplied insurance information, I authorize payment of my insurance benefits directly to DLS RESEARCH & VENTURES. I authorize DLS RESEARCH & VENTURES to be my Designated Representative and to appeal any denial of health benefits. I understand DLS RESEARCH & VENTURES may be out of network with my plan, and I accept responsibility for paying to DLS RESEARCH & VENTURES any amounts my insurer determines are my responsibility after calculating deductibles, co-payments, and co-insurance due under my policy. I understand I am legally responsible for sending DLS RESEARCH & VENTURES any money received from my health insurance company for performance of this laboratory test. I understand that consent is not a condition of purchasing any goods or services. I allow the release of medical information necessary to process this claim. I also acknowledge that I have received or been offered the Notice of Privacy Practices (NOPP) by my healthcare provider(s). Additional copies of our NOPP can be obtained on DLS RESEARCH & VENTURES website at www.dlsrav.com.

I further assign and transfer to DLS RESEARCH & VENTURES all rights, claims and causes of action against any person or entity who may be financially responsible for payment of my charges, and I consent to DLS RESEARCH & VENTURES independently or jointly with me or others, pursuing recovery against such persons or entities on its own behalf or in my place for the charges incurred in my care. The claims and causes of action that I assign include, but are not limited to, claims, or causes of action that I may have relating to any Health Plan, insurance policy or health benefits plan or any other party under ERISA, under state insurance law and under state common law. I further assign all rights, claims or causes of action I may have to request and obtain documents from any Health Plan/and its affiliated insurers, employers and third party administrators that relate to coverage or non-coverage of benefits or payment of charges for medical care rendered, including, without limitation, my certificate of coverage, policy and/or summary plan description; any master policy or governing plan document that differs from the certificate of coverage, policy and/or summary plan description; copies of any policies or procedures used to decide my claim; and a complete copy of any other claims adjudication information so that DLS RESEARCH & VENTURES can determine if a full and fair review of my claim took place.

TESTING CONSENT

I consent to having analysis performed and the results of the analysis made available to my physician (where requested). This signed test requisition form authorizes DLS RESEARCH & VENTURES to perform the test and disclose the results to my medical practitioner (where requested). No tests other than those requested above will be performed. I authorize DLS RESEARCH & VENTURES to retain this specimen for future testing as requested as long as any necessary physician orders for such testing are obtained and/or provided.

HEALTH CARE PRACTITIONER CONSENT

I have provided the patient with information about the genetic test being ordered and have obtained written, informed consent from the patient, or their legal representative, as required by applicable state law. If this order is for a minor, by submitting this order I attest that I have obtained the appropriate prior written consent from the parent or person authorized to consent for the minor.

I attest that the test is to assist in managing the treatment for a current condition, disease, illness, impairment, symptom, or disorder. I also affirm that this test is reasonable and medically necessary for this patient.

FOOTNOTES

(I) If the patient is under the age of 18, the health care provider's signature is required. If the patient is 18 or older, either the health care provider's or the patient's signature is required.

TEST REPORT

Reported disease-causing variants are described as pathogenic variant(s), likely pathogenic variants(s), or variant(s) of uncertain significance in genes interpreted to be responsible for, or potentially contributing to, a disease or condition. In addition, variants in genes not known to be associated with disease but for which there is evidence to suggest an association with disease may also be reported. When Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) tests are ordered by your HCP, you have the option to receive some findings not directly related to the reason for ordering the Test.



Jennifer Knaack, Director CLIA ID: 11D2114053 1700 Honey Creek Commons, Suite A, Conyers GA 30013

INFORMATION ABOUT PARENTAL AND FAMILIAL SAMPLES

In some circumstances, it may be helpful for additional family members to undergo testing in order to provide information that can aid in the interpretation of the WES/WGS test results. These Tests could be part of a TRIO Test or as stand-alone targeted testing. DLS RESEARCH & VENTURES, in consultation with the HCP, will decide if other family members need to be tested. If the HCP recommends testing for additional family members, only the Test performed will be reported. If undergoing a TRIO test (WES or WGS), parents will have the option of receiving a full parental report for an additional charge. If selected, the respective parental consent section must be completed below.

TEST LIMITATIONS

Due to current limitations in technology and incomplete knowledge of diseases and genes, some variants may not be detected by the Test ordered. There is a possibility that the Test result that is uninterpretable or of unknown significance may require further testing when more information is gained. In rare circumstances, Test results may be suggestive of a condition different from that which was originally considered for the purpose of consenting to this Test. The Test may also find variants or genes that lead to conditions for which you currently do not have symptoms or may not be related to your current condition.

Furthermore, all sequencing technologies have limitations. This analysis is performed by Next Generation Sequencing (NGS) and is designed to examine coding regions and splicing junctions. Although next generation sequencing technologies and our bioinformatics analysis significantly reduce the contribution of pseudogene sequences or other highly-homologous sequences, these may still occasionally interfere with the technical ability of the assay to identify pathogenic variant alleles in both sequencing and deletion/duplication analyses. Sanger sequencing is used to confirm variants with low quality scores and to meet coverage standards. If ordered, deletion/duplication analysis can identify alterations of genomic regions which include one whole gene (buccal swab specimens and whole blood specimens) and are two or more contiguous exons in size (whole blood specimens only); single exon deletions or duplications may occasionally be identified but are not routinely detected by this test. Identified putative deletions or duplications are confirmed by an orthogonal method (qPCR or MLPA). This assay will not detect certain types of genomic alterations which may cause disease such as, but not limited to, translocations or inversions, repeat expansions (e.g., trinucleotides or hexanucleotides), alterations in most regulatory regions (promoter regions) or deep intronic regions (greater than 20bp from an exon). This assay is not designed or validated for the detection of somatic mosaicism or somatic mutations.

TEST RISKS

Patients and family members may experience anxiety before, during, and/or after testing. Testing multiple family members may reveal that familial relationships are not biologically what they were assumed to be. For example, the Test may indicate nonpaternity (the stated father of an individual is not the biological father) or consanguinity (the parents of an individual are closely related by blood). These biological relationships may need to be reported to the HCP who ordered the test.

Under some circumstances an additional sample may be required for Tests to be performed. A positive test result may limit your access to health insurance or life assurance coverage; for example, a life insurance company might ask you to provide genetic information indicating a disorder if this information is available to you. Please refer to information on the Genetic Information Nondiscrimination Act (GINA) and applicable local laws for more information.

Patient Signature	 	Date